Molecular Insights Into Post-Cardiac Arrest Brain Injury Via CSF Multi-Omics
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChungnam National University Hospital
About this trial
The goal of this study is to uncover the molecular mechanisms responsible for secondary brain injury in patients with post-cardiac arrest syndrome by analyzing cerebrospinal fluid (CSF) using multi-omics techniques.
The main question this study aims to answer is:
Which genome-, transcriptome-, proteome-, and metabolome-level changes in CSF are associated with secondary brain injury after cardiac arrest?
To address this question, CSF samples collected from post-cardiac arrest patients will undergo multi-omics analyses. Identified molecular pathways will be used to screen existing drug databases and generate new therapeutic candidates through computational modeling and compound synthesis. These findings will provide the scientific foundation needed to design and implement future preclinical experiments using cardiac arrest animal models.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients receiving post-resuscitation care after out-of-hospital cardiac arrest for secondary brain injury treatment.
Uncontrolled diabetes.Coagulation disorders.
Thrombocytopenia (platelet count $< 100,000).
A history of cirrhosis diagnosis.
Disqualifiers
Cerebral Edema: Patients with evidence of cerebral edema on a brain computed tomography (CT) scan performed immediately after spontaneous circulation recovery.
Patients who underwent extracorporeal membrane oxygenation (ECMO).
Patients who could not maintain integrated therapy for more than 24 hours after cardiac arrest.
Patients with a history of acute or chronic brain disease.
Trial population
The study population for this research consists of a highly specific and clinically critical group of patients: Adults who have experienced out-of-hospital or in-hospital cardiac arrest and successfully regained spontaneous circulation (ROSC), but remain at high risk for secondary brain injury.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
60 Participants
are grouped into 2 trial groupsGroup A: Favorable neurological outcome
Group B: Unfavorable neurological outcome
Trial outcomes
Primary outcomes
1
Neurological outcome
Neurological outcome assessed using the Cerebral Performance Category (CPC) scale (range 1-5; lower scores indicate better neurological function).
Time frame
at discharge (assessed up to 3 days), 3 months after return of spontaneous circulation (ROSC)Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov